Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
Top Cited Papers
Open Access
- 1 May 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (5) , 728-734
Abstract
For the past 5 decades, the randomized clinical trial (RCT) has been the standard to establish efficacy of new cancer therapies. However, there have been important changes in RCT design and end points since its widespread adoption in the 1970s. In 2008, our group described characteristics of RCTs published in major journals during the era of cytotoxic chemotherapy (1975-2004) for breast, colorectal, and non–small cell lung cancers.1 During this period, the size of RCTs increased substantially; primary end points shifted from response rate to overall survival (OS); the proportion of trials with a statistically significant difference in favor of the experimental arm doubled (23% to 42%); and, although the magnitude of benefit did not change over time, authors of modern recent RCTs were more likely to strongly endorse the experimental arm as a new standard of care. We also reported a major shift in funding: while government grants supported most RCTs (60%) in the 1970s and 1980s, by the late 1990s and early 2000s, 57% of trials were funded by industry. Finally, our original overview demonstrated sponsorship bias (ie, independent of effect size and statistical significance, industry-funded trials are more likely to be “positive”—defined in the present study as RCTs in which the primary end point has a statistically significant difference in favor of the experimental arm).Keywords
This publication has 29 references indexed in Scilit:
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and CreativityJAMA Otolaryngology–Head & Neck Surgery, 2014
- High Cancer Drug Prices in the United States: Reasons and Proposed SolutionsJournal of Oncology Practice, 2014
- Progression-Free Survival: Meaningful or Simply Measurable?Journal of Clinical Oncology, 2012
- Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end pointsAnnals of Oncology, 2011
- Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical TrialsJournal of Clinical Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancerAnnals of Oncology, 2009
- Evolution of the Randomized Controlled Trial in Oncology Over Three DecadesJournal of Clinical Oncology, 2008
- The uncertainty principle and industry-sponsored researchThe Lancet, 2000